Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JCAR017 + CC-99282
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous (JCAR017), Oral (CC-99282)
01
Overview
JCAR017 + CC-99282 is an investigational combination therapy for relapsed or refractory B-cell malignancies, notably including various forms of non-Hodgkin lymphoma. **JCAR017 (lisocabtagene maraleucel)** is a CD19-directed, autologous, genetically modified chimeric antigen receptor (CAR) T cell therapy. It reprograms the patient's own T cells to target and kill CD19-expressing B cells, a hallmark of many lymphomas. **CC-99282** is an oral CELMoD (cereblon E3 ligase modulator) small molecule designed to degrade Ikaros and Aiolos proteins, key transcription factors in B-cell malignancy survival, thereby enhancing T-cell and NK-cell mediated cytotoxicity. The combination is being evaluated to determine safety, tolerability, and effectiveness in B-cell lymphomas[1][3][4][6].
- Brand names
- Breyanzi (for JCAR017)
- Other names
- lisocabtagene maraleucel + CC-99282
02
Targets
CD19 (B lymphocyte antigen CD19)IKZF1 (Ikaros family zinc finger protein 1)CRBN (Cereblon)ZFP91 (Zinc finger protein 91)IKZF3 (Zinc finger protein Aiolos)
Beyond the preview
Go deeper on JCAR017 + CC-99282.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JCAR017 + CC-99282.